Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – HC Wainwright issued their Q3 2026 EPS estimates for Bradmer Pharmaceuticals in a report released on Thursday, August 6th. HC Wainwright analyst M. Colonnese forecasts that the company will earn ($0.24) per share for the quarter. HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($1.39) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.21) EPS, Q4 2027 earnings at ($0.17) EPS and FY2027 earnings at ($0.94) EPS.
Separately, Chardan Capital upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy”.
Bradmer Pharmaceuticals Stock Performance
Recommended Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
